Table 1.
Baseline patient characteristics of the patent group and the occluded group.
| Patent (112) | Occluded (22) | P | |
|---|---|---|---|
| Age | 63.0 (57.0–69.0) | 59.0 (56.0–68.3) | 0.567 |
| Female (n, %) | 26 (23.2) | 6 (27.3) | 0.785 |
| BMI | 25.4 (23.0–27.7) | 26.1 (24.3–27.8) | 0.505 |
| Hypertension (n, %) | 79(70.5) | 12 (54.5) | 0.210 |
| Diabetes (n, %) | 46(41.1) | 5 (22.7) | 0.149 |
| Insulin treatment | 14 (12.5) | 2 (9.1) | 1.000 |
| Hyperlipidemia (n, %) | 56 (50.0) | 10 (45.5) | 0.817 |
| Previous stroke (n, %) | 9 (8.1) | 4 (18.2) | 0.229 |
| Smoking (n, %) | 32 (28.6) | 6 (27.3) | 1.000 |
| PVD (n, %) | 15 (13.4) | 4 (18.2) | 0.517 |
| Ventricular aneurysm (n, %) | 4 (3.6) | 0 (0.0) | 1.000 |
| Previous MI (n, %) | 22 (19.6) | 1 (4.5) | 0.122 |
| PCI | 18(16.2) | 4 (18.2) | 0.761 |
| Arrhythmia (n, %) | 3 (2.7) | 1 (4.5) | 0.516 |
| AMI (n, %) | 28 (25.0) | 7 (31.8) | 0.596 |
| Diseased vessels | 3.0 (2.0–3.0) | 3.0 (3.0–4.0) | 0.912 |
| Left main disease (n, %) | 24 (21.4) | 10 (45.5) | 0.030 |
| NYHA (n, %) | 0.361 | ||
| I | 0 (0.0) | 1 (4.5) | |
| II | 87 (77.7) | 17 (77.3) | |
| III | 24 (21.4) | 4 (18.2) | |
| IV | 1 (0.9) | 0 (0.0) | |
| LVEF (%) | 64.1 (56.6–68.7) | 64.6 (59.2–72.3) | 0.239 |
| LVEF <40% (n, %) | 2 (1.8) | 1 (4.5) | 0.421 |
| EuroSCORE II | 1.0 (0.8–1.5) | 0.9 (0.6–1.6) | 0.886 |
| Triglycerides | 1.5 (1.1–2.0) | 1.4 (1.2–1.8) | 0.996 |
| PLT | 195.0 (172.0–238.3) | 218.0 (175.5–273.8) | 0.091 |
| Preoperative creatinine (μmol/ml, ±s) | 71.0 (61.3–84.8) | 66.5 (57.8–82.0) | 0.818 |
BMI, body mass index; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular diseases; PCI, percutaneous coronary intervention; AMI, acute myocardial infarction; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVEDd, left ventricular end-diastolic dimension; PLT, platelet count.